Prostatic Artery Embolization Market Growing Geriatric Population to Boost Growth 2028 | Mentice AB, Merit Medical Systems, Boston Scientific Corporation, Siemens Healthineers AG,

Growing Geriatric Population to Boost Prostatic Artery Embolization Market Growth

Global Prostatic Artery Embolization Market, by Region (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa) – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2020 – 2027

The global prostatic artery embolization market is estimated to exhibit a CAGR of 4.5% over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Prostatic artery embolization (PAE) is emerging as an effective minimally invasive treatment for lower urinary tract symptoms caused by benign prostatic hyperplasia. PAE has a high rate of success, with over 90% of individuals experiencing relief in the first year. Prostatic artery embolization is a safe treatment with long term efficacy. It can be a viable therapeutic option for patients with severe lower urinary tract symptoms (LUTS) from giant prostatic hyperplasia (GPH) whom fail medical therapy and are not candidates for surgical treatments.

𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: (𝐈𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐅𝐮𝐥𝐥 𝐓𝐎𝐂, 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐓𝐚𝐛𝐥𝐞𝐬 & 𝐅𝐢𝐠𝐮𝐫𝐞𝐬, 𝐂𝐡𝐚𝐫𝐭) @ https://www.coherentmarketinsights.com/insight/request-pdf/4108

Benign prostatic hyperplasia affects more than 50% of men by the age of 60 years and up to 80% of men older than 70 years, and its prevalence is increasing as the population ages. Benign prostatic hyperplasia (BPH) is an enlargement of the prostate caused by an overgrowth of cells (called hyperplasia) in the prostate.

Competitive Landscape:

Major players operating in the global prostatic artery embolization market are GE Healthcare, QXMedical, LLC, Embolx, Inc., Terumo Corporation, Merit Medical Systems, Inc., Mentice AB, Siemens Healthineers AG, and Boston Scientific Corporation, among others.

Key Market Drivers:

Increasing prevalence of benign prostate hyperplasia across the globe is expected to augment the growth of the prostatic artery embolization market during the forecast period. For instance, worldwide, as many as 30 million men have symptoms related to benign prostatic hyperplasia. According to the National Institutes of Health (NIH), BPH affects about 50% of men between the ages of 51 and 60 and up to 90% of men older than 80.

𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐂𝐨𝐯𝐢𝐝𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 @ https://www.coherentmarketinsights.com/insight/request-sample/4108

Moreover, growing adoption of prostatic artery embolization procedures is expected to boost the growth of the prostatic artery embolization market. For instance, in July 2018, physicians at UC San Diego Health started offering prostate artery embolization (PAE) as a new treatment option for men with benign prostatic hyperplasia (BPH). The minimally invasive procedure is an alternative to surgery, with no hospital stay, little operative pain, and lower cost.

COVID-19 Impact Analysis:

The outbreak of COVID-19 has had severe impact on the growth of various markets, and it is also expected to hinder growth of the prostatic artery embolization market during the forecast period. Moreover, safety measures enforced by several countries, as well as, safety precautions suggested by World Health Organization (WHO), to reduce the risk of spread of COVID-19 infection while performing surgical procedures it has become very difficult to conduct surgical procedures, such as prostatic artery embolization.

Key Takeaways:

• The prostatic artery embolization market is expected to exhibit a CAGR of 4.5 % during the forecast period due to the growing geriatric population around the world. For instance, according to WHO, the world’s population of people aged 60 years and older will double (2.1 billion) by 2050, and the number of individuals aged 80 years or older is expected to triple between 2020 and 2050, to reach 426 million.
• Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the prostatic artery embolization market owing to the high prevalence of benign prostate hyperplasia, growing geriatric population, and growing adoption of prostatic artery embolization procedures in these regions.
• For instance, as many as 14 million men in the United States have symptoms of BPH. In July 2018, the University of California, San Diego (UCSD) researchers announced that the Food and Drug Administration (FDA) approved prostate artery embolization, or PAE, to treat benign prostate hyperplasia, or enlarged prostates. Moreover, PAE has been available in Europe as a treatment option for an enlarged prostate for several years.